Lefamulin acetate

• CAT Number: I017896
• CAS Number: 1350636-82-6
• Molecular Formula: C₃₀H₄₉NO₇S
• Molecular Weight: 567.78
• Purity: 98%
• Target: Bacterial
• Target Protein: P61182
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: acetic acid;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate
• InChI: InChI=1S/C28H45NO5S.C2H4O2/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28;1-2(3)4/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3;1H3,(H,3,4)/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+;/m1./s1
• InChIKey: WSMXIQXWHPSVDE-ZPJPNJFZSA-N
• SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C.CC(=O)O

Lefamulin acetate（Cat No.:I017896）, commercially known as Xenleta or BC-3781 acetate, is a pleuromutilin antibiotic utilized for treating community-acquired bacterial pneumonia (CABP). It exerts its antimicrobial effect by inhibiting protein synthesis. Lefamulin acetate specifically binds to the peptidyltransferase center within the 50S bacterial ribosome, hindering the binding of transfer RNA to the peptide transfer. By disrupting this crucial step in protein synthesis, lefamulin acetate effectively impedes bacterial growth and combats CABP, offering a valuable therapeutic option for this type of infection.

Reference

[1]. Veve MP, et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.